International API supplier Olon has announced a set of investments in its high containment manufacturing global platform. $31m (€27m) has been allocated for the expansion of internal expertise and high containment production throughout 2022 and 2023. HPAPIs and biotech are key areas of focus for the company throughout this expansion period.
Target therapies, i.e. drugs that are selective and therefore better tolerated by the patient, have an action that targets only the mechanism underlying the development of the disease. Improvements in treatment selectivity result in a demand for increasingly potent active pharmaceutical ingredients.
The company recently completed a large-scale high containment production line (OEL < 1 mg/m3) at its site in Rodano. Batches of HPAPIs ranging from 30 to 250 kg can be produced on the line, serving the customer at all the stages of scale up. Starting with a few grams in a GMP laboratory, the group has the internal flexibility needed to move on to batches of 1 or 2 kg, then tens of kilograms, followed by the 30 to 250 kg range with recently installed line.
“Now we are one of the few CDMO companies to offer the range of specific integrated capabilities necessary to support the customer from the first clinical phase up to industrialization, regardless of the quantity of product needed and batch size required and regardless of the ongoing molecule development phase” said Paolo Tubertini, CEO of Olon Group.
“With the investments announced today. We keep on driving the leadership of this technology in the industry. The expertise in high containment processes is evident from the equipment we have at our disposal, but even more so from the in-house know-how that we have developed in recent decades, among the most extensive in the global API manufacturing market.”
